JP2024506384A5 - - Google Patents

Info

Publication number
JP2024506384A5
JP2024506384A5 JP2023548873A JP2023548873A JP2024506384A5 JP 2024506384 A5 JP2024506384 A5 JP 2024506384A5 JP 2023548873 A JP2023548873 A JP 2023548873A JP 2023548873 A JP2023548873 A JP 2023548873A JP 2024506384 A5 JP2024506384 A5 JP 2024506384A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
patient
roflumilast
ophthalmic pharmaceutical
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548873A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506384A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/015942 external-priority patent/WO2022173923A1/en
Publication of JP2024506384A publication Critical patent/JP2024506384A/ja
Publication of JP2024506384A5 publication Critical patent/JP2024506384A5/ja
Pending legal-status Critical Current

Links

JP2023548873A 2021-02-10 2022-02-10 ロフルミラストの眼科的送達方法 Pending JP2024506384A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163148008P 2021-02-10 2021-02-10
US63/148,008 2021-02-10
US202163261404P 2021-09-20 2021-09-20
US63/261,404 2021-09-20
PCT/US2022/015942 WO2022173923A1 (en) 2021-02-10 2022-02-10 Methods for ophthalmic delivery of roflumilast

Publications (2)

Publication Number Publication Date
JP2024506384A JP2024506384A (ja) 2024-02-13
JP2024506384A5 true JP2024506384A5 (cg-RX-API-DMAC7.html) 2025-02-19

Family

ID=82704332

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548873A Pending JP2024506384A (ja) 2021-02-10 2022-02-10 ロフルミラストの眼科的送達方法

Country Status (8)

Country Link
US (2) US12102622B2 (cg-RX-API-DMAC7.html)
EP (1) EP4291162A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024506384A (cg-RX-API-DMAC7.html)
AU (1) AU2022218993A1 (cg-RX-API-DMAC7.html)
CA (1) CA3206106A1 (cg-RX-API-DMAC7.html)
IL (1) IL304924A (cg-RX-API-DMAC7.html)
MX (1) MX2023009352A (cg-RX-API-DMAC7.html)
WO (1) WO2022173923A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12263160B2 (en) * 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases
AR130498A1 (es) * 2022-09-16 2024-12-11 Iolyx Therapeutics Inc Composiciones farmacéuticas de alta concentración de roflumilast para administración oftálmica
AU2024298631A1 (en) * 2023-07-25 2026-02-05 Iolyx Therapeutics, Inc. Ocular surface topical administration of roflumilast for treatment of anterior and retinal-vitreous chamber ocular diseases

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ290266B6 (cs) 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
SK122199A3 (en) 1997-03-18 2000-12-11 Basf Ag Methods and compositions for modulating responsiveness to corticosteroids
BR0013793A (pt) * 1999-09-06 2002-05-14 Ono Pharmaceutical Co Medicamentos profiláticos e terapêuticos para doenças oftálmicas
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
JP3805203B2 (ja) * 2001-02-16 2006-08-02 日本油脂株式会社 点眼用水性懸濁製剤およびその製造方法
US6872382B1 (en) 2001-05-21 2005-03-29 Alcon, Inc. Use of selective PDE IV inhibitors to treat dry eye disorders
IL160271A0 (en) 2001-09-19 2004-07-25 Altana Pharma Ag Pharmaceutical compositions containing pde4-inhibitors and nsaid
US20060084684A1 (en) * 2002-05-28 2006-04-20 Altana Pharma Ag Topically applicable pharmaceutical preparation
US20060263350A1 (en) 2003-09-26 2006-11-23 Fairfield Clinical Trials Llc Combination antihistamine medication
WO2006028618A1 (en) 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
NZ585697A (en) 2004-08-02 2011-12-22 Univ Virginia Patent Found 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
DE102004046235A1 (de) 2004-09-22 2006-03-30 Altana Pharma Ag Arzneimittelzubereitung
ES2421916T3 (es) * 2005-03-16 2013-09-06 Nycomed Gmbh Forma farmacéutica de sabor enmascarado que contiene roflumilast
SI1885336T1 (sl) 2005-05-10 2009-08-31 Alcon Inc Suspenzijske formulacije, ki obsegajo aktivno sestavino, poloksamerni ali meroksapolni surfaktant in glikol, in njihova uporaba za pripravo zdravila za zdravljenje oftalmičnih motenj
AU2006244245B2 (en) 2005-05-10 2010-11-18 Alcon, Inc. Ophthalmic suspension comprising an ophthalmic drug, a poloxamine and a glycol tonicity-adjusting agent, use of said composition for the manufacture of a medicament for treating ophthalmic disorders
JP2007016024A (ja) * 2005-06-09 2007-01-25 Santen Pharmaceut Co Ltd ロフルミラスト点眼液
WO2006132342A1 (ja) * 2005-06-09 2006-12-14 Santen Pharmaceutical Co., Ltd. ロフルミラスト点眼液
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
DK2250161T3 (da) 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet
CN103508936A (zh) 2008-08-22 2014-01-15 赛诺菲-安万特 用于制备吲哚苄胺化合物的中间体
MX2012006401A (es) 2009-12-03 2012-07-10 Lupin Ltd Proceso para preparar composiciones oftalmicas farmaceuticas.
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
AU2012232658B2 (en) 2011-03-22 2016-06-09 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
JP6363506B2 (ja) * 2011-11-15 2018-07-25 アラーガン、インコーポレイテッドAllergan,Incorporated シクロスポリンa2型の懸濁剤
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
HK1214159A1 (zh) 2012-11-08 2016-07-22 Rhizen Pharmaceuticals S.A. 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
WO2015132708A1 (en) 2014-03-07 2015-09-11 Torrent Pharmaceuticals Limited Pharmaceutical composition of roflumilast
WO2016024185A1 (en) 2014-08-12 2016-02-18 Pfizer Inc. Pyrrolo[2,3-d]pyrimidine derivatives useful for inhibiting janus kinase
TW201729810A (zh) 2015-10-26 2017-09-01 札爾科製藥公司 嘧啶組成物、其超純組成物及鹽類、製造彼之方法、及使用彼於治療組織胺h4受體(h 4 )仲介之疾病與病情之方法
US9895359B1 (en) 2017-06-07 2018-02-20 Arcutis, Inc. Inhibition of crystal growth of roflumilast
WO2020081622A1 (en) 2018-10-16 2020-04-23 Research Triangle Institute Subcutaneous biodegradable reservoir device
EP4061332A4 (en) 2019-11-24 2023-11-29 Sol-Gel Technologies Ltd. TREATMENT OF SKIN DISEASES USING TOPICAL COMPOSITIONS CONTAINING TAPINAROF AND A PDE4 INHIBITOR
US12263160B2 (en) * 2021-09-22 2025-04-01 Iolyx Therapeutics, Inc. Methods of treating ocular inflammatory diseases

Similar Documents

Publication Publication Date Title
US20260124178A1 (en) Presbyopia treatments
Chun et al. Iris and trabecular meshwork pigment changes after posterior chamber phakic intraocular lens implantation
JP2006524185A5 (cg-RX-API-DMAC7.html)
JP2015509500A5 (cg-RX-API-DMAC7.html)
JP2013535472A (ja) 防腐剤無添加ビマトプロストおよびチモロール溶液
Stojanovic et al. 200 Hz flying-spot technology of the LaserSight LSX excimer laser in the treatment of myopic astigmatism: six and 12 month outcomes of laser in situ keratomileusis and photorefractive keratectomy
JP2015523986A5 (cg-RX-API-DMAC7.html)
RU2014151992A (ru) Лечение воспалительных заболеваний глаз с применением лахинимода
MX2023009352A (es) Metodos para la administracion oftalmica de roflumilast.
RU2707379C1 (ru) Способ выбора параметров лазерного воздействия при лечении далекозашедшей и терминальной рефрактерной глаукомы
Zheng et al. Angle-closure glaucoma following periorbital botulinum toxin injection.
RU2668703C1 (ru) Способ хирургического лечения первичной открытоугольной глаукомы
RU2164112C1 (ru) Способ лечения постконтузионных повреждений глаза
RU2743218C1 (ru) Способ хирургической коррекции пресбиопии у лиц среднего и пожилого возраста - тканесохранный ЛАСИК
Sakai et al. Recurrent uveal effusion after laser iridotomy
Espana et al. Cyclodialysis cleft secondary to removal of an anterior chamber phakic intraocular lens
RU2585400C2 (ru) Лекарственная форма на основе бутиламиногидроксипропоксифеноксиметил метилоксадиазола
US20250387331A1 (en) Prostaglandin analogs and methods for sustained glaucoma management
RU2688960C1 (ru) Способ комбинированного хирургического лечения вторичной глаукомы, вызванной эмульгированием силикона
RU2294183C2 (ru) Способ проведения операции рефракционно-коррегирующей эксимерлазерной интрастромальной кератэктомии (рэик)
Taniguchi et al. A risk-benefit assessment of drugs used in the management of glaucoma
RU2731885C2 (ru) Способ профилактики пигментной глаукомы при синдроме пигментной дисперсии
Uva et al. Pneumatic trabeculoplasty versus argon laser trabeculoplasty in primary open-angle glaucoma
RU2638767C1 (ru) Способ профилактики реактивной гипертензии после факоэмульсификации катаракты
Woodward Anterior capsulotomy of dislocated lenses in Marchesani syndrome using a Nd: YAG laser